Readmissions following umbilical cord blood stem cell transplantation.
Jennifer L. Crombie(Dana-Farber Cancer Institute), Brett Glotzbecker(Dana-Farber Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Shuli Li(Unknown), Robert J. Soiffer(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Contribution of bone marrow–derived endothelial cells to human tumor vasculature
|Nature Medicine|2005|480